Stockreport

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01 [Yahoo! Finance]

Evaxion Biotech A/S - American Depositary Share  (EVAX) 
PDF Trial on track for one-year clinical efficacy readout in Q3 2024 COPENHAGEN, Denmark, April 17, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” [Read more]